22 June 2018

Executive from Merck KGaA, Darmstadt, Germany re-emphasises the importance of addressing the treatment gap of preschoolers infected with schistosomiasis

Initiation of the Phase III development program by the Pediatric Praziquantel Consortium announced at the WHA Schistosomiasis luncheon in Geneva on May 22nd, 2018

The WHA Schistosomiasis luncheon, organized by Merck KGaA, Darmstadt, Germany is an event which showcases continued engagement in the fight against schistosomiasis.  It brings together Ministers of Health from African countries, ambassadors and high-level representatives from the Global Health community as well as key players from the field of Neglected Tropical Diseases.

As per previous years, this event has given the opportunity to the Pediatric Praziquantel Consortium partners present at the event (Lygature, Schistosomiasis Control Initiative, Swiss Tropical & Public Health Institute and Merck KGaA) to share an update of the program, currently preparing for Phase III, with key stakeholders and funders, including the Global Health Innovative Technology (GHIT) Fund. 

The program has been referenced during the official speeches, including the one from Prof. Dr. Stangenberg-Haverkamp (Chairman of the Executive Board and Family Board of Merck KGaA, Darmstadt, Germany) who highlighted the importance of this project to close the treatment gap for children below six year of age suffering from schistosomiasis.

Furthermore, the booth at the event provided an additional opportunity of showcasing the new orodispersible tablets (ODTs) used in clinical testing and, through live experiments, its rapid dissolution – all to confirm the progress and achievements of the program.

Image: Dr. Mama Fouda (Minister of Public Health of Cameroon) in the middle; Dr. Elly Kourany-Lefoll (Lead of the Consortium Pediatric Praziquantel Formulation program and Head of Global Health Development Program, Global Health Institute at Merck KGaA, Darmstadt, Germany) on the left;  Dr. Jutta Reinhard-Rupp (Chair of the Consortium Board and Head of the Global Health Institute at Merck KGaA, Darmstadt, Germany) on the right.